Kymera Therapeutics Inc. (KYMR) Social Stream

Featured Post From StockTwits About KYMR

$BYSI Seed therapeutics, a 60% owned subsidiary of BYSI, is a majorly interesting wildcard. Got a LLY deal for $800M bio bucks. Explores the red hot field of Targeted Protein Degradation ( $ARVN, $KYMR ). Seeks a different, closer to small molecules way of accomplishing ubiquitination of targets than the complex PROTACS. Wants to target first the holy grail of cancer, the undruggable KRAS.
If this subsidiary can successfully mark-and-sweep mutated KRAS, it will dwarf its parent company.

What Else are KYMR Traders Talking About?

Other tickers frequently mentioned alongside KYMR are BYSI and ARVN.